Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY 315920

Known as: LY-315920, LY315920, LY333013 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

varespladib methyl

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)
Snakebite is a global tropical disease that has long had huge implications for human health and well-being. Despite its long… Expand
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2018
2018
Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of Micrurus fulvius (Eastern Coral Snake) Venom
OBJECTIVE There is a clear, unmet need for effective, lightweight, shelf-stable and economical snakebite envenoming therapies… Expand
  • figure 1
  • figure 2
  • figure 5
  • table 1
  • table 2
Is this relevant?
2018
2018
Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom
There is an unmet need for economical snakebite therapies with long shelf lives that are effective even with delays in treatment… Expand
  • figure 1
Is this relevant?
2016
2016
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation
Snakebite remains a neglected medical problem of the developing world with up to 125,000 deaths each year despite more than a… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
We report a series of inhibitors of secreted phospholipases A2 (sPLA2s) based on substituted indoles, 6,7-benzoindoles, and… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2005
2005
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
OBJECTIVE To evaluate the efficacy and safety of a selective inhibitor of secretory phospholipase (sPLA2), LY333013, in the… Expand
Is this relevant?
2005
2005
Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16.
PURPOSE How vitamin A contributes to the maintenance of the wet-surfaced phenotype at the ocular surface is not well understood… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2005
2005
Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma.
The possible roles of secretory phospholipases A2 (sPLA2) in asthma include the release of arachidonic acid from cellular… Expand
Is this relevant?
1999
1999
Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti…
LY315920 is a potent, selective inhibitor of recombinant human, group IIA, nonpancreatic secretory PLA2 (sPLA2). In a chromogenic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 6
Is this relevant?
1996
1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
The preceding papers of this series detail the development of functionalized indole-3-acetamides as inhibitors of hnps-PLA2. We… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE